Business Description
Gabather AB
SIC : 2834
ISIN : SE0010869552
Total Employee Number:
2Compare
Compare
Traded in other countries / regions
GABA.Sweden5J2.Germany IPO Date
2020-08-13Description
Gabather AB is a Swedish pharmaceutical research and development company focused on drugs that act on the central nervous system. Its work centers on modulating the GABA-A receptor system, and its lead candidate, GT-002, is being developed for conditions such as schizophrenia, anxiety, and other psychiatric and neurological disorders. The company's pipeline spans antipsychotic, antidepressant, anxiolytic, analgesic, and cognition-enhancing programs, including potential treatments for Alzheimer's disease. As a clinical-stage development company, Gabather does not market finished pharmaceutical products; instead it generates value through research, preclinical and clinical testing, and intellectual property, seeking to out-license candidates or partner with larger pharmaceutical firms for later-stage development and commercialization. Its activities are based in Sweden, with collaboration and financing relationships extending internationally. Revenue, when present, typically derives from research grants, licensing arrangements, or partnership agreements rather than product sales.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.32 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 47.7 | |||||
3-Year EPS without NRI Growth Rate | 50.2 | |||||
3-Year FCF Growth Rate | 40.6 | |||||
3-Year Book Growth Rate | -68.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.46 | |||||
Quick Ratio | 1.46 | |||||
Cash Ratio | 1.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -100.9 | |||||
Shareholder Yield % | -22.56 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -1853.12 | |||||
ROA % | -114.74 | |||||
ROIC % | -136 | |||||
3-Year ROIIC % | 214.55 | |||||
ROCE % | -1802.67 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 15.1 | |||||
EV-to-EBIT | -2.83 | |||||
EV-to-EBITDA | -2.83 | |||||
EV-to-FCF | -2.07 | |||||
Earnings Yield (Greenblatt) % | -35.29 | |||||
FCF Yield % | -40.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gabather AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.002 | ||
| Beta | 0.7194 | ||
| 3-Year Sharpe Ratio | -0.47 | ||
| 3-Year Sortino Ratio | -0.69 | ||
| Volatility % | - | ||
| 14-Day RSI | 48.15 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 0.0002 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.0002 - 0.015 | ||
| Shares Outstanding (Mil) | 610.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gabather AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gabather AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 157 days | ||
| Third quarter earnings results for 2026 | 2026-11-27 | In 66 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | 0.00 (+0.00%) | ||
| General meeting for 2026 | 2026-06-26 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2026-05-29 | 0.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-29 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 0.00 (1,900.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-27 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-28 | 0.00 (+0.00%) | ||
| General meeting for 2025 | 2025-06-30 11:00 | 0.00 (+0.00%) |
Show
Entries
Gabather AB Frequently Asked Questions
What is Gabather AB(FRA:5J2)'s stock price today?
The current price of FRA:5J2 is €0.00. The 52 week high of FRA:5J2 is €0.02 and 52 week low is €0.00.
When is next earnings date of Gabather AB(FRA:5J2)?
The next earnings date of Gabather AB(FRA:5J2) is 2026-11-27.
Does Gabather AB(FRA:5J2) pay dividends? If so, how much?
Gabather AB(FRA:5J2) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Gabather reports initial positive results from the EEG/fMRI target engagement study | 2024-03-07 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers